Compare AGNC Investment Corp (AGNC) vs Ascendis Pharma A/S (ASND) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AGNC Investment Corp vs Ascendis Pharma A/S — how do they compare? AGNC Investment Corp trades at $10.95 (market cap $12.91B), while Ascendis Pharma A/S trades at $256.21 (market cap $16.67B). The key difference: Ascendis Pharma A/S is the larger of the two by market cap, and AGNC Investment Corp pays a 13.22% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| AGNC | ASND | |
|---|---|---|
Market Cap | $12.91B | $16.67B |
Sector | Financials | Health |
52-Week High | $12.17 | $277.18 |
52-Week Low | $9.46 | $189.74 |
Dividend Yield | 13.22% | — |
Enterprise Value | — | $17.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AGNC Investment Corp. trades at $10.955, up 1.81% today, with a bullish technical signal from moving averages. The mortgage REIT reported strong profitability with a 94.38% net income margin and 21.67% ROE. Recent earnings beat expectations in Q1 and Q2 2026, though Q4 2025 missed. The company maintains a consistent monthly dividend, recently paying $0.12 per share. Analyst consensus price target is $11.30, suggesting modest upside from current levels.
AGNC offers high yield income potential with a secure dividend history, but faces interest rate sensitivity as a leveraged mREIT. Revenue growth from $1.8B in 2025 to $2.4B projected for 2026 supports dividend sustainability. Primary risks include mortgage spread compression and Federal Reserve policy changes. Institutional ownership trends show continued interest, with CalPERS increasing its stake in 2026.
Ascendis Pharma (ASND) trades at $255.50, showing minimal daily movement with a slight decline of 0.05%. The stock maintains a bullish technical outlook with strong moving average signals, while oscillators remain neutral. Fundamentally, the company demonstrates impressive revenue growth from $51M in 2022 to $720M in 2025, though it remains unprofitable with a net loss of $228M. Analyst sentiment is overwhelmingly positive with 92% buy ratings and a $309.75 consensus price target representing 21% upside potential.
ASND presents a compelling growth story with multiple product launches driving revenue expansion, but carries significant execution risk as the company transitions to profitability. The negative shareholder equity and high debt levels require careful monitoring, though positive cash flow generation in 2025 marks an important inflection point. The stock's premium valuation reflects expectations for continued growth in its rare endocrine franchise.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AGNC Investment Corp
AGNC Investment Corp is a real estate investment trust that invests in agency residential mortgage-backed securities. The firm's asset portfolio is comprised of residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by a U.S. Government-sponsored enterprise, such as the Federal National Mortgage Association and the Federal Home Loan Mortgage Corporation, or by a U.S. Government agency, such as the Government National Mortgage Association. It also invests in other types of mortgage and mortgage-related residential and commercial mortgage-backed securities or other investments in or related to, the housing, mortgage or real estate markets.
Read more on AGNC →About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →
